Vuong Trieu

CIK: 0001587074

Transaction Breakdown

Open Market Buys (P)15 (83.3%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (16.7%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

OTLC

Oncotelic Therapeutics, Inc.

DirectorOfficer10% Owner

Discretionary Trading P&L

Holdings

Transaction History (18 total)

OTLC
Oncotelic Therapeutics, Inc.
Oct 29, 2026
Purchase(P)
Direct
1M shares at avg. $0.02$18K
OTLC
Oncotelic Therapeutics, Inc.
Oct 28, 2026
Purchase(P)
Direct
312K shares at avg. $0.02$6K
OTLC
Oncotelic Therapeutics, Inc.
Jul 10, 2026
Award(A)
Restricted stock Units
Direct
2K shares-
OTLC
Oncotelic Therapeutics, Inc.
Jul 1, 2026
Purchase(P)
Direct
240K shares at avg. $0.04$10K
OTLC
Oncotelic Therapeutics, Inc.
Jun 24, 2026
Purchase(P)
Direct
115K shares at avg. $0.04$5K
OTLC
Oncotelic Therapeutics, Inc.
Jun 23, 2026
Purchase(P)
Direct
75K shares at avg. $0.04$3K
OTLC
Oncotelic Therapeutics, Inc.
Jun 22, 2026
Purchase(P)
Direct
65K shares at avg. $0.04$3K
OTLC
Oncotelic Therapeutics, Inc.
Jun 17, 2026
Purchase(P)
Direct
239.8K shares at avg. $0.04$11K
OTLC
Oncotelic Therapeutics, Inc.
Jun 15, 2026
Purchase(P)
Direct
96K shares at avg. $0.04$4K
OTLC
Oncotelic Therapeutics, Inc.
Jan 22, 2026
Award(A)
Series A Convertible Preferred Stock
Direct
4.4K shares-
OTLC
Oncotelic Therapeutics, Inc.
Nov 17, 2025
Award(A)
Series A Convertible Preferred Stock
Direct
4.1K shares-
OTLC
Oncotelic Therapeutics, Inc.
Jul 10, 2025
Purchase(P)
Direct
104K shares at avg. $0.01$520
OTLC
Oncotelic Therapeutics, Inc.
Jul 9, 2025
Purchase(P)
Direct
1 shares at avg. $0.01$0.005
OTLC
Oncotelic Therapeutics, Inc.
Jul 8, 2025
Purchase(P)
Direct
94.7K shares at avg. $0.01$473.68
OTLC
Oncotelic Therapeutics, Inc.
Jan 31, 2025
Purchase(P)
Direct
63.8K shares at avg. $0.03$2K
OTLC
Oncotelic Therapeutics, Inc.
Jan 30, 2025
Purchase(P)
Direct
100K shares at avg. $0.03$3K
OTLC
Oncotelic Therapeutics, Inc.
Jan 29, 2025
Purchase(P)
Direct
183.1K shares at avg. $0.03$5K
OTLC
Oncotelic Therapeutics, Inc.
Nov 22, 2024
Purchase(P)
Direct
298.5K shares at avg. $0.03$9K

		Type	Shares	Price		Ownership
Oct 29, 2026	OTLC Oncotelic Therapeutics, Inc.	Purchase(P)	1,044,990	$0.02	$17,765	Direct
Oct 28, 2026	OTLC Oncotelic Therapeutics, Inc.	Purchase(P)	312,000	$0.02	$5,772	Direct
Jul 10, 2026	OTLC Oncotelic Therapeutics, Inc.	Award(A) Restricted stock Units	2,000	-	-	Direct
Jul 1, 2026	OTLC Oncotelic Therapeutics, Inc.	Purchase(P)	240,000	$0.04	$10,344	Direct
Jun 24, 2026	OTLC Oncotelic Therapeutics, Inc.	Purchase(P)	115,000	$0.04	$5,175	Direct
Jun 23, 2026	OTLC Oncotelic Therapeutics, Inc.	Purchase(P)	75,000	$0.04	$3,375	Direct
Jun 22, 2026	OTLC Oncotelic Therapeutics, Inc.	Purchase(P)	65,000	$0.04	$2,925	Direct
Jun 17, 2026	OTLC Oncotelic Therapeutics, Inc.	Purchase(P)	239,759	$0.04	$10,693	Direct
Jun 15, 2026	OTLC Oncotelic Therapeutics, Inc.	Purchase(P)	96,000	$0.04	$4,320	Direct
Jan 22, 2026	OTLC Oncotelic Therapeutics, Inc.	Award(A) Series A Convertible Preferred Stock	4,426	-	-	Direct
Nov 17, 2025	OTLC Oncotelic Therapeutics, Inc.	Award(A) Series A Convertible Preferred Stock	4,065	-	-	Direct
Jul 10, 2025	OTLC Oncotelic Therapeutics, Inc.	Purchase(P)	104,000	$0.01	$520	Direct
Jul 9, 2025	OTLC Oncotelic Therapeutics, Inc.	Purchase(P)	1	$0.01	$0	Direct
Jul 8, 2025	OTLC Oncotelic Therapeutics, Inc.	Purchase(P)	94,736	$0.01	$474	Direct
Jan 31, 2025	OTLC Oncotelic Therapeutics, Inc.	Purchase(P)	63,775	$0.03	$1,786	Direct
Jan 30, 2025	OTLC Oncotelic Therapeutics, Inc.	Purchase(P)	100,003	$0.03	$2,800	Direct
Jan 29, 2025	OTLC Oncotelic Therapeutics, Inc.	Purchase(P)	183,066	$0.03	$5,126	Direct
Nov 22, 2024	OTLC Oncotelic Therapeutics, Inc.	Purchase(P)	298,499	$0.03	$8,627	Direct

1-18 of 18 transactions

About Trieu Vuong

Trieu Vuong (SEC CIK 0001587074) files insider reports with the SEC as CHAIRMAN AND CEO of Oncotelic Therapeutics, Inc. (OTLC).

Signal8 holds 10 ownership filings by Trieu Vuong, all Form 4s, filed between Nov 26, 2024 and Oct 30, 2026. Those filings report 18 transactions, from Nov 22, 2024 to Oct 29, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Trieu Vuong's filings is in AGOURA HILLS, CA.

Recent filings by Trieu Vuong

Oct 29, 2026: Open-market purchase of OTLC shares (Form 4, code P).
Oct 28, 2026: Open-market purchase of OTLC shares (Form 4, code P).
Jul 10, 2026: Grant or award of OTLC derivative securities (Form 4, code A).
Jul 1, 2026: Open-market purchase of OTLC shares (Form 4, code P).
Jun 24, 2026: Open-market purchase of OTLC shares (Form 4, code P).

Other insiders filing for Oncotelic Therapeutics, Inc. (OTLC)

Fein Seymour Howard, CRO/CMO
KING STEVEN W, Director
MAIDA ANTHONY E III, DIRECTOR AND CMO - TRANS. MED.
Saund Saran, CBO
Shah Amit B., CFO

How to read Form 4 transaction codes